Photo taken from Vivek Subbiah/LinkedIn
Sep 13, 2023, 14:04
Vivek Subbiah: Super thrilled to share our paper – Variant of allele frequency: a decision-making tool in precision oncology?
Vivek Subbiah, Chief, Early-Phase Drug Development, Sarah Cannon Research Institute, made the following post on LinkedIn:
“Hot off the press: Super thrilled to share our paper – Variant of allele frequency: a decision-making tool in precision oncology? – published in a Cell Press journal Trends in Cancer !
An absolute delight to collaborate with the amazing Giuseppe Curigliano & his terrific team among many others.
PrecisionMedicine Sarah Cannon Research Institute.
A great pre-read before ESMO23 and MAP23 meetings”
For details click here
Source: Vivek Subbiah / LinkedIn
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 4, 2025, 00:02
Sep 3, 2025, 22:35
Sep 3, 2025, 22:09
Sep 3, 2025, 20:48
Sep 3, 2025, 20:35
Sep 3, 2025, 20:10
Sep 3, 2025, 19:42